The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026 - Seite 2

Global WholeHealth Partners Corp (OTC Pink: GWHP) BREAKING NEWS:  Autistic Spectrum of Disorders (ASD) Are Now Diagnosable; This Medical Breakthrough was Attained by Global WholeHealth Partners, Corp (OTC: GWHP) as Leading Researcher, and Believes an ASD Epidemic is on the Horizon - Global WholeHealth Partners Corp, a multinational supplier of over 70+ FDA Approved Diagnostic Tests, attains breakthrough on rising neurological disease. As stated by the CDC, ASD are growing quickly. About 1 in 54 children has been identified with autism spectrum disorder (ASD) according to estimates from CDC's Autism and Developmental Disabilities Monitoring (ADDM) Network.

About 1 in 6 (17%) children aged 3–17 years were diagnosed with a developmental disability, as reported by parents, during a study period of 2009-2017. These included autism, attention-deficit/hyperactivity disorder, blindness, and cerebral palsy, among others.

What is Autistic Spectrum of Disorders? The Autistic Spectrum of Disorders is more than Autism; it encompasses several disorders. Global WholeHealth Partners now has the means to identify and test for ASD using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis. This was disclosed in an 8K filing which can be found by clicking here .

"We believe this announcement couldn't come at a better time for us as we are working with Nunzia Pharmaceutical and their future treatment for ASD," said Mr. Strongo. "Early detection for ASD disease is not only crucial for patients and their quality of life, but this data is also used by researchers to seek out commonalities, causes and hopefully cures," commented Strongo.

Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp, said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests."  CONTINUED… Read more news for the Global WholeHealth news at:  https://investors.gwhpcorp.com/category/news/